In early development, First-in-Human (FIH) is often described as a milestone, but in practice, it represents a transition point.
Moving from development planning into clinical execution requires more than a validated non-clinical package and a compliant CMC strategy. It requires an operational framework capable of sustaining regulatory scrutiny, ensuring patient safety, and supporting reliable data generation.
As outlined in the broader development roadmap, FIH readiness is not defined by a single deliverable, but by the alignment of multiple elements.
Clinical operations, safety systems, governance structures, and regulatory compliance must all be in place before dosing begins. Regulators are not only assessing the product, but they are also assessing the organisation behind it.
In this blog post
- What operational readiness means in a First-in-Human context
- The core components of a minimal FIH operational framework
- What regulators expect to see before dosing begins
- Where operational readiness typically breaks down in emerging biotechs
First-in-Human Readiness as a Transition Into Clinical Execution
Regulatory frameworks from EMA, MHRA, and FDA consistently emphasise that clinical trials must be conducted under conditions that ensure subject safety and data integrity.
ICH E6 (GCP), adopted across regions, makes the sponsor responsible for the initiation, management, and oversight of the trial.
In practical terms, this means that FIH is not just about whether the data package supports clinical entry. It is about whether the organisation is ready to operate under clinical conditions.
Before dosing begins, sponsors must be able to demonstrate:
- Quality systems are in place
- Roles and responsibilities are clearly defined
- Vendor oversight is structured
- Safety monitoring processes are operational
Without this foundation, even a well-designed study becomes difficult to execute reliably.
A Practical Framework for First-in-Human Operational Readiness
A useful way to approach FIH readiness is to view the required operational components as part of a single, coordinated system rather than isolated elements.
At this stage, four areas typically define whether a program is ready to move forward:
Clinical Trial Design
Ensuring that the protocol is scientifically justified, feasible in practice, and clearly linked to non-clinical data and risk mitigation strategies.
Site and Investigator Readiness
Confirming that selected sites have the required infrastructure, trained personnel, and experience, including specific expertise in the proposed therapy, to manage early-phase studies safely.
Safety Management and Monitoring
Including real-time oversight, clearly defined stopping rules, and escalation pathways for emerging risks.
Sponsor Governance and Infrastructure
Covering roles, responsibilities, vendor oversight, and the quality system supporting trial execution, with clear processes to enable agile decision-making and ensure the right stakeholders are consulted.
These elements are interdependent. A robust protocol without capable sites, or a strong safety plan without clear governance, creates execution risk.
What matters is not whether each component exists individually, but whether they function together as a coherent system that supports safe and controlled trial conduct.
What Regulators Expect Before First-in-Human Trials
From a regulatory perspective, FIH readiness is not assessed through a single document, but through the consistency and credibility of the overall submission and operational setup.
Authorities expect to see:
- Alignment between non-clinical data, clinical design, and risk mitigation measures
- Evidence that the investigational product is suitable for clinical use
- Clear safety monitoring processes and escalation pathways
- Defined roles and organisational responsibilities
- A level of organisational maturity supporting compliance with GCP
In the EU, these aspects are evaluated under the Clinical Trials Regulation (CTR). In the US, they form part of the IND framework. In the UK, similar expectations apply under MHRA processes, including the updated Clinical Trials legislation implemented in April 2026.
Although procedures differ, the underlying principle remains the same. Regulators assess whether the trial can be conducted safely and reliably from day one.
Common Operational Pitfalls in First-in-Human Readiness
In emerging biotech environments, the main challenges are rarely related to individual technical elements, but to how those elements are connected and managed.
Treating Operational Setup as a Post-Submission Activity
Operational readiness is often addressed too late. Many components must already be in place or clearly defined before submission, not after.
Unclear Ownership Across Functions
Responsibilities across clinical, quality, safety, and regulatory domains are not always clearly assigned, and the availability of relevant stakeholders is not always ensured, leading to inconsistencies in documentation, decision-making, and execution.
Underestimating Vendor Oversight
CROs and external partners are engaged, but governance models are not sufficiently defined. This can impact data quality, timelines, and compliance.
Safety Frameworks Without Operational Clarity
Safety processes may exist on paper but lack practical definition, particularly regarding real-time decision-making and escalation pathways.
First-in-Human Readiness Defines Clinical Execution Success
First-in-Human is often described as the start of clinical development, but in reality, it is the point at which the entire development strategy is tested under real conditions.
Operational readiness determines whether that transition is controlled or reactive.
When clinical design, site readiness, safety management, and governance are aligned, the program progresses with confidence. When they are not, delays and risks emerge quickly.
For emerging biotechs, the objective is not to build complex organisations, but to establish a minimum framework that is clear, functional, and inspection-ready.
When this is done early, First-in-Human becomes not just a milestone, but a stable foundation for the rest of development.
Strengthening Your First-in-Human Operational Readiness
Preparing for First-in-Human trials requires alignment across clinical, safety, quality, and regulatory domains.
QbD Group supports biotech companies in:
- Designing FIH-ready operational frameworks
- Establishing governance and vendor oversight models
- Ensuring GCP-compliant clinical execution
- Preparing organisations for regulatory interactions and inspections
References
EMA. Clinical Trials Regulation (EU) No 536/2014 https://health.ec.europa.eu/medicinal-products/clinical-trials/clinical-trials-regulation-eu-no-5362014_en
EMA. Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-mitigate-risks-first-human-early-clinical-trials_en.pdf
ICH E6(R2). Good Clinical Practice https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf
FDA. Investigational New Drug (IND) Application https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
MHRA. Clinical trials for medicines https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk
About the Author
Director Regulatory Affairs UK
Sacha has over 20 years of experience in European Regulatory Affairs with expertise spanning product development to post approval. Her educational background includes a degree in pharmacology and medical sciences, complemented by a master's in clinical research. Currently she is a Principal consultant with QbD Group, where she continues to support clients and leads project teams to develop robust strategies in their clinical development. Sacha actively contributes to the profession and leads the introductory course for TOPRA.
End-to-End Support from Strategy to First-in-Human
Move confidently from preclinical development to CTA readiness and early clinical execution. We support emerging biotech teams with integrated regulatory, quality, CMC, and safety expertise, built for speed without compromising credibility.
Learn moreSubscribe to the latest updates in life science
Expert perspectives delivered to your inbox — pick your interests.
No spam, ever. Unsubscribe anytime.
